Safety and Tolerance of a Nutritional Intervention Program- In.Form 1.2
NCT ID: NCT03098056
Last Updated: 2017-04-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2016-08-01
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Preventative Screening and Health Coaching in a Food Insecure Population
NCT06907524
Pharmacist-led Therapeutic Nutritional Intervention in Type 2 Diabetes
NCT03181165
Individualized Nutrition Therapy for Preventing or Delaying Onset of Type-2 Diabetes
NCT05161897
Lifestyle Intervention in Obese Non-diabetic Adults With a Family History of Diabetes.
NCT00993603
Evaluation of Nutritional Prevention Program for Women's Cardiovascular Health on Quality of Life (SAFE)
NCT06380218
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PROG2
All subjects will be participating in a lifestyle change program - specifically a high protein, limited carbohydrate food plan (High Phyto-PRO food plan), physical activity and a cognitive behavioral program consisting of 11 group visit. Participants will be recieving nutritional Supplements.
PROG2
Nutritional Supplements to be administered:
* Protein Shakes: one shake po twice daily
* Phytosterol supplement: one capsule po twice daily
* Cinnamon: one tablet twice daily
* Fiber supplement; one shake twice daily
* Antioxidant supplement: 2 capsules daily with dinner
* Fish Oil supplement: 1 capsule twice daily with food
* Probiotic supplement: 1 capsule twice daily with food
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PROG2
Nutritional Supplements to be administered:
* Protein Shakes: one shake po twice daily
* Phytosterol supplement: one capsule po twice daily
* Cinnamon: one tablet twice daily
* Fiber supplement; one shake twice daily
* Antioxidant supplement: 2 capsules daily with dinner
* Fish Oil supplement: 1 capsule twice daily with food
* Probiotic supplement: 1 capsule twice daily with food
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* to be overweight or obese (BMI ≥ 27 kg/m2 and ≤ 50 kg/m2),
* to exhibit visceral obesity (waist circumference ≥ 35 inches for women and ≥ 39 inches for men),
* and demonstrate signs of cardiometabolic dysfunction. Specifically, subjects were required to have:
* elevated LDL cholesterol ≥ 130 mg/dl
* and/or elevated TG defined as TG ≥ 130 mg/dl. Additionally, subjects were required to have at least one of the following criteria (unless subject had both elevated LDL and TG):
* HDL \< 50 mg/dl for women and \< 40 mg/dl for men,
* blood glucose ≥ 100 mg/dl, HbA1C ≥ 5.7%,
* or Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) score defined as ≥ 2.0.
Exclusion Criteria
* Lactation
* Recent changes in prescription medications, over-the-counter medications, medical foods, and nutritional supplements
* Recent or regular use of narcotics, investigational drugs, corticosteroids, anticoagulants, neuroactive medications, or medication or supplements relevant to hyperglycemia or hyperlipidemia
* Chronic use of over-the-counter medication which would interfere with study endpoints including NSAIDS, laxatives and antacids
* Allergy or intolerance to study products
* Serious, unstable medical conditions including known infection with HIV, tuberculosis or hepatitis; cardiovascular disease; Diabetes Mellitus; autoimmune diseases; malignancy; psychiatric disease; substance abuse;
* Abnormal laboratory findings
* Participating in or planning to begin a weight loss diet during the study period
* Difficulty in swallowing pills
* Lifestyle or schedule incompatible with the study protocol.
18 Years
69 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nature's Sunshine Products, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joseph J Lamb, MD
Role: PRINCIPAL_INVESTIGATOR
Hughes Center for Research and Innovation
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NSP-CT-010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.